Amphastar Pharmaceuticals (AMPH) Invested Capital (2013 - 2026)

Amphastar Pharmaceuticals has reported Invested Capital for 14 years, with the latest figure at $1.4 billion in Q2 2026.

• On a quarterly basis, Invested Capital rose 1.03% year-over-year to $1.4 billion in Q2 2026; TTM through Jun 2026 was $1.4 billion, a 1.03% increase from a year earlier, with the FY2025 full-year figure at $1.4 billion, up 4.87% from the prior year.
• Invested Capital was $1.4 billion for Q2 2026 at Amphastar Pharmaceuticals, roughly flat from $1.4 billion in the prior quarter.
• The five-year high for Invested Capital was $1.4 billion in Q4 2025, with the low at $556.0 million in Q1 2022.
• Average Invested Capital over 5 years is $1.1 billion, with a median of $1.3 billion recorded in 2024.
• The sharpest annual moves came in 2023 and 2026: Invested Capital soared 112.41% in 2023, then rose 1.03% in 2026.
• Over 5 years, Invested Capital stood at $604.5 million in 2022, then soared by 103.37% to $1.2 billion in 2023, then rose by 8.52% to $1.3 billion in 2024, then advanced by 4.87% to $1.4 billion in 2025, then slipped by 1.36% to $1.4 billion in 2026.
• The last three Invested Capital figures came in at $1.4 billion (Q2 2026), $1.4 billion (Q1 2026), and $1.4 billion (Q4 2025), per Business Quant data.